Skip to main content
. 2017 Jan 23;58(1):114–122. doi: 10.1093/jrr/rrw081

Table 4.

Comparison of clinical outcomes of early-stage nasal extranodal NK/T-cell lymphoma in recent publications

Author No. of pts Ann Arbor stage (%) Treatment types (No. of pts) CT regimen (No. of pts) RT dose(cGy) Response (%) 5-year OS (%) 5-year PFS (%) ≥ Grade 3
Toxicity (n)a
Avilés et al. (2013)b [2] 427

  • I (58)

  • II (41)

  • RT alone (109)

  • C/T alone (116)

  • RT→C/T (202)

 CMED (318) 5500

  • 69

  • 59

  • 91

  • 64

  • 45

  • 86

  • 78

  • 40

  • 91

  • 11

  • 14

  • 33
Li et al. (2013) [13] 73

  • I/II (44)

  • IV (24)

  • CT alone (14)

  • RT alone (8)

  • C/T + RT (42)

 CHOP like 46 Median PFS 3yrs
Wang et al. (2012) [21] 42

  • I (81)

  • II (19)

  • RT alone (23)

  • C/T+RT (19)* All use IMRT

 CHOP like (19) 5000
(median)		 95.2 78 (2-year) 74 (2-year) 7
Jayoung Lee et al. (2013) [25] 24

  • I (83.3)

  • II (16.7)

  • RT→C/T (4)

  • C/T→RT (12)

  • C/T→RT→C/T (8)

  • CHOP (16)

  • ProMACE-CytaBOM (7)

  • Other (1)

 4500
(median)		 83.3 70.3 66.2

  • 3 (acute)

  • 4 (late)
Jieun Lee et al. (2013)b [26] 43

  • I (72)

  • II (28)

  • C/T→RT (16)

  • CCRT (27)

  • CHOP like (SCRT)

  • Weekly cisplatin (CCRT)

  • 5400

  • 4500

  • 94

  • 96

  • 75

  • 59

(3-year)

  • 56

  • 41

(3-year)

  • 8

  • 6
Jiang et al. (2012) [27] 26

  • I, Limited (50)

  • I, Extensive (26.9)

  • II (23.1)

 C/T→RT→C/T L-VP (26) 5600 88.5 88.5
(2-year)		 80.6
(2-year)		 2
Oh et al. (2015) [28] 62

  • I (74.2)

  • II (25.8)

 CCRT→C/T

  • Cisplatin for CCRT

  • VIPD/VIDL/MIDLE for C/T

 4000 96.7 83.1
(3-year)		 77.1
(3-year)		 3
Yang et al. (2015) [29] 1273

  • I (74.4)

  • II (25.6)

  • RT alone (253)

  • C/T alone (170)

  • RT→C/T (209)

  • C/T→RT (641)

  • CHOP like (826)

  • L-asparaginase based (126) Gemcitabine based (68)

 5000
(median)		 93.3

  • Stage I: 67.6

  • Stage II: 51.3

  • Stage I: 58.3

  • Stage II: 44.0

 –
Present study 37

  • I (78.4)

  • II (21.6)

  • RT alone (8)

  • C/T→RT/CCRT (24)

  • CCRT (1)

  • C/T→RT→C/T (4)

  • CHOP like (16)

  • L-VP (8)

  • Others (5)

 5000
(median)		 91.2 76.3
(3-year)		 64.0
(3-year)		 6

C/T = chemotherapy, RT = radiotherapy, No. of pts = Number of patients, ProMACE-CytaBOM = cyclophosphamide + doxorubicin + etoposide + cytozar + bleomycin + vincristine + methotrexate + prednisone, CHOP = cyclophosphamide + adriamycin + vincristine + prednisolone, L-VP = L-asparaginase + vincristine + prednisolone, CMED = cyclophosphamide + methotrexate + etoposide + dexamethasone, VIPD = etoposide + ifosfamide + cisplatin + dexamethasone, VIDL = etoposide + ifosfamide + dexamethasone followed by intramuscular injection of L-asparaginase, MIDLE = methotrexate + etoposide + ifosfamide + mesna + L-asparaginase, OS = overall survival, PFS = progression-free survival, SCRT = sequential chemoradiotherapy, CCRT = concurrent chemoradiotherapy.

aAcute toxicity according to CTCAE or RTOG, n as number of toxicity events.

bResponse, OS, PFS, toxicity according to different treatment types.